Pages that link to "Q37321208"

The following pages link to Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? (Q37321208):

Displaying 16 items.

• High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance (Q28474284) (← links)
• Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer (Q34433737) (← links)
• Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers (Q35029573) (← links)
• Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer (Q36244265) (← links)
• Ki67 in breast cancer: prognostic and predictive potential (Q37691691) (← links)
• Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review (Q37858233) (← links)
• Biomarkers for cervical cancer screening: the role of p16(INK4a) to highlight transforming HPV infections (Q37998530) (← links)
• Evaluation of HER2 in breast cancer: reality and expectations. (Q38089837) (← links)
• Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). (Q38347216) (← links)
• TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer (Q39336778) (← links)
• The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin (Q44312601) (← links)
• Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients. (Q54618083) (← links)
• Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer (Q60529816) (← links)
• TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers (Q64239576) (← links)
• Breast cancer: Increasing therapy options for HER2-positive early breast cancer (Q83080583) (← links)
• Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy (Q84382547) (← links)